April 26, 2018
InSysBio LLC (www.insysbio.com) – pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development – announced today further collaboration with GSK - one of the world’s leading research-based pharmaceutical and healthcare companies - to expand the previously developed QSP model of asthma.
The companies together have constructed a complex asthma model which facilitated the investigation of novel medicines and combination therapy scenarios. GSK has chosen InSysBio as a partner to implement a further expansion of the existing model. This will include new targets and clinical trial data to be able simulate more asthma treatment scenarios.
“We chose to work with InSysBio because of their rich experience in QSP modeling and fundamental knowledge in the field. Through this partnership, we hope to continue to improve drug development in asthma”, David Fairman, Senior Director Clinical Pharmacology Modelling and Simulation, GSK, Lourdes Cucurull-Sanchez, Manager Target Sciences, GSK.
“We are very pleased that GSK decided to continue work with us. It means InSysBio has shown itself as a partner with significant expertise and strength in QSP”, Oleg Demin Jr, Head of Business Development, InSysBio.
About InSysBio
InSysBio (formerly Institute for System Biology Moscow) was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of quantitative systems pharmacology (QSP) modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published a lot of scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | July 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
|
7
1.
07 Jul 2021 12:40
InSysBio to present its posters at AAIC 2021
InSysBio announces its participation in AAIC 2021 (Online). Alzheimer's Association International Conference is held in Denver, USA and Online in July 26-30, 2021. InSysBio Neurodegeneration Diseases team presents two posters within its frames
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
1.
22 Jul 2021 16:03
InSysBio to present Immune Response Template v. 3.5.0
Now IRT gets significant update and a portion of new data
[Moscow – 22.07.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.5.0.
|
23
|
24
|
25
|
|
26
|
27
|
28
1.
28 Jul 2021 16:26
InSysBio to take part in ESMO Congress 2021
InSysBio announces its participation in ESMO (European Sosiety For Medical Oncology) Virtual Congress 2021 which is held on September 16-21. InSysBio team's abstract was accepted
|
29
|
30
|
31
| |
Thank you for your message! We will get back to you shortly.
